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Abstract
As it is likely that both common and rare genetic variation are important for complex disease risk, 
studies that examine the full range of the allelic frequency distribution should be utilized to dissect 
the genetic influences on mental illness. The rate limiting factor for inferring an association 
between a variant and a phenotype is inevitably the total number of copies of the minor allele 
captured in the studied sample. For rare variation, with minor allele frequencies of 0.5% or less, 
very large samples of unrelated individuals are necessary to unambiguously associate a locus with 
an illness. Unfortunately, such large samples are often cost prohibitive. However, by using 
alternative analytic strategies and studying related individuals, particularly those from large 
multiplex families, it is possible to reduce the required sample size while maintaining statistical 
power. We contend that using whole genome sequence (WGS) in extended pedigrees provides a 
cost-effective strategy for psychiatric gene mapping that complements common variant approaches 
and WGS in unrelated individuals. This was our impetus for forming the “Pedigree-Based Whole 
Genome Sequencing of Affective and Psychotic Disorders” consortium. In this review, we provide 
a rationale for the use of WGS with pedigrees in modern psychiatric genetics research. We begin 
with a focused review of the current literature, followed by a short history of family-based 
research in psychiatry. Next, we describe several advantages of pedigrees for WGS research, 
including power estimates, methods for studying the environment, and endophenotypes. We 
conclude with a brief description of our consortium and its goals.
Large-scale genome wide association studies (GWAS) comprise the dominant paradigm in 
psychiatric genetics research today [1]. Case/control GWAS, that compare the frequency of 
minor alleles from common polymorphisms between unrelated individuals [2], have 
provided numerous insights into the genetic architecture [1] and the interrelatedness [3, 4] of 
psychiatric disorders. However, like any experimental approach, the case/control GWAS 
design has relative strengths and weaknesses. Unfortunately, it is unlikely that any single 
design will be able to dissect all of the genetic influences on multifactorial traits [5, 6] such 
as mental illnesses [7, 8]. Rather, diverse complementary approaches may be necessary to 
garner the full spectrum of biological insights that genetics could provide neuropsychiatry 
[5, 9–12]. Chief among these approaches is the use of whole genome sequencing (WGS) 
which catalogues almost all genomic DNA sequence variation within an organism [13]. 
Early sequencing efforts confirmed that the substantial majority of human genetic variation 
is rare (occurring in less than 1% of the population) or private (only occurring in a single 
individual and their close relatives) [13, 14]. There is a growing appreciation of the impact 
of rare variation on human disease [11, 15, 16], particularly given the excess of rare 
functional variants resulting from recent accelerated population growth and relatively weak 
purifying selection [17]. Rare variants, especially loss of function variants or those 
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deleterious to protein expression, are far more amenable to biological experimentation, and 
subsequent molecular insights, than common loci [18–22], which are often localized outside 
of transcribed regions [23, 24]. As it is likely that both common and rare variation are 
relevant for complex diseases [11], both GWAS and WGS methods should be utilized in a 
complementary manner to dissect the genetic influences on mental illness.
The rate limiting factor for inferring an association between a particular rare variant and a 
phenotype is inevitably the total number of copies of that variant captured in the sample [25–
27]. Typically, to have enough copies of a rare variant for statistical analysis, one must 
sequence very large samples of unrelated individuals (e.g., ~700,000 in the recent human 
height exome study [20]). Consistent with this notion, the Whole Genome Sequencing of 
Psychiatric Disorders (WGSPD) consortium estimated that sequences from at least 20,000 
unrelated cases and controls are needed to adequately power a gene burden-type analysis [8], 
though far larger samples are necessary to identify specific risk variants for mental illness. 
However, by using alternative analytic strategies and studying related individuals, 
particularly those from large multiplex families, it is possible to reduce the required sample 
size while maintaining statistical power [28–31]. Given this and other benefits discussed 
below, we contend that WGS in extended pedigrees provides a cost-effective strategy for 
psychiatric gene mapping that complements GWAS and WGS in unrelated individuals. In 
fact, family-based methods may be the only feasible study design for specifically identifying 
the rarest functional variants that are private to family lineages. This was our impetus for 
forming the “Pedigree-Based Whole Genome Sequencing of Affective and Psychotic 
Disorders” consortium, an international group of scientists using family-based designs to 
identify rare variants that increase risk for psychiatric disorders.
In this review, we provide a rationale for the use of WGS with pedigrees in modern 
psychiatric genetics research. We begin with a focused review of the current literature, 
followed by a short history of family-based research in psychiatry. Next, we describe several 
advantages of pedigrees for WGS research, including power estimates, methods for studying 
the environment, and utilizing endophenotypes. We conclude with a brief description of our 
consortium and its goals.
The current state of psychiatric genetics
Large-scale GWAS meta-analyses have been successfully completed for schizophrenia 
(sample size: 36,989 cases/113,075 controls [32]), bipolar disorder (13,902/19,279 [33], 
9,784/30,471 [34]), major depression (130,664/330,470 [35], 10,851/32,211 [36], 
121,380/338,101 [37]), post-traumatic stress disorder (5131/15,092 [38]), attention deficit 
hyperactivity disorder (20,183/35,191 [39]), and autism (16,539/157,234 [40]). Together, 
these GWAS have localized over 200 genome-wide significant loci influencing mental 
illness risk [1]. Given the sample sizes listed above, it is quite possible that common loci 
with moderate to large effect sizes for the majority of mental illnesses have already been 
localized [10], at least among individuals of European ancestry. If so, this represents an 
important milestone for the field and provides an opportunity to explore alternate approaches 
for delineating the genetics of mental illness.
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One lesson from GWAS is that mental illnesses, like other complex diseases, appear to be 
highly polygenic, involving large numbers of loci, most of which have a small or very small 
effect on risk [10, 41, 42]. This pattern of results is entirely consistent with Fisher’s 
multifactorial model [43], which predicts that as the number of risk loci grows, the 
contribution of each new locus correspondingly shrinks. Accordingly, results from meta-
analyses have been used for individual risk prediction based on polygenic scores [44, 45] 
that include thousands to hundreds of thousands of variants to provide a risk index [46]. 
Additionally, loci from GWAS studies appear to be useful for selecting among potential 
therapeutic agents [47], a property which could have a significant impact in psychiatry [48] 
where novel drug development is at a near standstill [49].
A case for rare genetic variants in mental illness
Arguably, our understanding of the genetic underpinnings of autism spectrum disorders has 
advanced more than that of other mental illnesses because investigators have focused more 
on rare nonsynonymous variants [50] than common genetic variation [40]. These studies, 
which often search for exonic de novo mutations [51, 52], have identified at least 50 
potential risk genes for the disorder that together with copy number variants (CNV) explain 
more than 30% of the genetic variance of the illness [53, 54]. While the relative contribution 
of largest-effect common variants and of higher-penetrance rare variants probably varies 
across mental illnesses [1, 55, 56], the genetic architecture of autism is likely not unique. For 
example, Singh and colleagues identified a set of rare, putative loss-of-function variants in 
an exon SETD1A that strongly increases risk for schizophrenia and intellectual disability 
[57]. Similarly, exome sequencing studies in schizophrenia have implicated genes expressed 
in neurons [58] and synapses [59] and shown that affected individuals have more rare 
protein-altering loss-of-function variants than unrelated controls [58].
Perhaps the strongest evidence that rare variation is important across mental illnesses [60] 
comes from findings that certain rare CNVs or insertion-deletions clearly influence risk for 
autism spectrum disorders [61], intellectual disability [62] and schizophrenia [63, 64], and 
may also contribute to bipolar disorder [65] and ADHD [66] risk. Indeed, the 22q11 CNV 
[67] is among the strongest genetic predictors of schizophrenia risk [63, 68].
Family studies in psychiatric genetics
Historically, the mapping of traits to genetic loci in humans depended almost exclusively on 
family studies. Early linkage studies posited simple, single major gene models of inheritance 
and utilized transmission of chromosome segments across generations in large pedigrees to 
map putative disease loci relative to a scaffold of a few hundred markers of known position. 
Later linkage approaches did not assume a Mendelian model and utilized identity-by-descent 
(IBD) allele sharing among relatives. Although these linkage methods successfully identified 
loci for some illnesses (e.g., Huntington’s disease, Alzheimer’s disease, macular 
degeneration, diabetes, and some forms of breast cancer), early attempts to localize the 
genetic influences on polygenic diseases were limited and often could not be replicated. 
Indeed, two early high profile reports of linkages for bipolar disorder, one on the X 
chromosome [69] and the other on 11p [70], could not be replicated [71, 72]. When 
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reviewing this literature in 2008, Burmeister and colleagues [73] reported that no single 
locus was unequivocally replicated across multiple independent samples for any mental 
illness. This lack of results was likely due to underpowered studies that used suboptimal 
concordant sibling pair designs [73, 74] and were likely ineffectual where very rare or 
private mutations were causal. Nonetheless, discouraging progress with linkage analyses, 
combined with the simplicity of sampling unrelated cases and controls, undoubtedly added 
to the popularity of association methods and the field’s shift towards GWAS.
In an influential article, Risch and Merikangas [75] argued that linkage analysis has limited 
power to detect genes of modest effect (particularly in concordant sibling pair designs), but 
that family-based assocation methods have far greater power to detect the same loci, 
provided the locus is either directly genotyped or in strong linkage disequilibrium (LD) with 
a genotyped marker. The genome-wide application of this association strategy was made 
possible by the human genome project’s identification and mapping of hundreds of 
thousands of common genetic variants and the characterization of patterns of LD between 
them. It draws on shared population history rather than transmission among family 
members, to map loci of interest. This information, in turn, allowed investigators to estimate 
minor allele frequencies (MAF) and LD-structure for singletons, enabling GWAS in 
unrelated individuals [2]. Yet, the reliance on population level knowledge has drawbacks. 
For example, GWAS are population-specific. Most published GWAS have been in European-
derived populations, where the LD structure is well defined and represented on GWAS 
arrays. Although work is ongoing, sample sizes in non-European populations are yet to 
reach levels that would support powerful GWAS [76]. Carefully ascertained, very large 
families do not require population level information (e.g., MAF or LD-structure), have the 
potential to provide sufficient copies of very rare alleles to identify their effects, and offer 
the opportunity to leverage both analytical approaches, combining genome-wide association 
and examination of familial transmission within the same analysis. Thus, while family-based 
designs were largely set aside in the GWAS era, the recurring focus on rare variants and 
functional genomics have renewed interests in pedigrees.
Rare variants and pedigrees
Pedigree-based studies represent an implicit enrichment strategy for identifying rare variants 
as transmission of a rare allele from parents to offspring follows Mendel’s laws, maximizing 
the chance that multiple copies of that allele exist in the pedigree. For example, 148 
individuals from a single large pedigree sampled in our ongoing “Genetics of Brain 
Structure and Function” study [77, 78] are represented in Fig. 1. Based on the principles of 
Mendelian inheritance, the pedigree could maximally provide 105 copies of a rare or even 
private mutation originating in a single founder (founder and unilineal descendants). While 
the propagation of a particular variant within a pedigree is likely less extreme than this, the 
example provides an important heuristic for understanding how families enrich even the 
rarest of genetic variation where the segregation of rare variants in a pedigree provides 
multiple copies, facilitating their detection and effect estimation [29, 31, 79, 80]. For a 
known pedigree, each founding lineage can be directly assessed for the expected number of 
copies of a private variant originating at the top of the lineage using Mendelian transmission 
probabilities. The expected number of copies of a private variant originating in the focal 
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founder of Fig. 1 is 13 (as is that of his founder spouse). While this founder pair exhibits the 
maximum number of potential copies, the founder female spouse of the third male sibling in 
generation II actually exhibits the highest expectation of potential copies with 14.125.
For a fixed biological effect size, the power of pedigrees for capturing larger numbers of rare 
minor allele copies than that expected in an equivalent set of unrelated individuals is a direct 
function of pedigree structure. Basically, the variance of the number of minor allele copies 
(MACs) can be substantially larger (and therefore lead to potentially many more copies) in 
pedigrees than in a sample of unrelated individuals. Given that the expected correlation 
structure for the allelic dosages amongst family members is well represented by the 
coefficient of relationship matrix, R, standard covariance mathematics reveal that the 
expected excess in the variance of expected MACs in a pedigree can be approximated by a 
multiplicative variance inflation factor, VIF = ∑i, jri j/n where rij is the coefficient of 
relationship between the i-th and j-th individuals in the pedigree and n is the number of 
individuals in the pedigree. The larger the VIF for a pedigree, the greater the expected power 
is for capturing larger numbers of a private variant, which itself determines the expected 
power to detect an association of a rare variant conditional on biological effect size. A 
sibship yields a VIF equal to1 + (n – 1)(1/2), thus a large sibship of 10 siblings generates a 
VIF of 5.5 times that expected for 10 unrelated individuals. The pedigree shown in Fig. 1 
generates a VIF of 8.6. Typically, large pedigrees with large lineages will yield the highest 
VIFs likely to be observed in humans. Thus, pedigrees are optimally suited for the 
examination of rare functional variants because in the limiting case of private variants, 
traditional epidemiological studies of unrelated individuals are highly unlikely to capture 
more than a single copy of such a variant (e.g., [58, 59, 81]). Pedigree-based studies could 
capture many more depending upon the size and structure of the pedigrees. However, a 
potential negative for such studies is the more limited number of genomes being observed 
over that of unrelated samples. For example, the pedigree in Fig. 1 represents independent 
genomes from 44 founders versus that 148 that would be observed if all these individuals 
were unrelated. Thus, while more copies of rare variants can be captured in pedigrees, we 
also expect fewer such variants overall than in samples of unrelated individuals.
For rare variants in the absence of inbreeding, the number of heterozygotes captured is a 
primary determinant of statistical power to detect association. In this case, the number of 
heterozygotes is equivalent to the number of minor allele copies captured in the sample. 
Following theory developed in Blangero and colleagues [82], the expected association test 
statistic for private variants in pedigrees can be approximated (for small relative effects) as:
χ1
2 ≈ Nhq
2 − c hT
2 , hq
2,R = NH(1 − H)α2 − c hT
2 , hq
2,R
where N is the sample size, hq
2
 is the heritability due to the variant in the sample, hT
2
 is the 
total heritability of the trait, H is the proportion of heterozygotes in the sample, and α is the 
displacement of the heterozygote mean trait value from the common homozygote in standard 
deviation units. The parameter, α, directly measures the biological effect size of the variant. 
The symbol c() represents a function of parameters within the parentheses and is used here 
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as a correction that accounts for the non-independence amongst related individuals and is 
defined in detail elsewhere [82]. The value of c is generally small for most reasonable 
genetic effect sizes [82]. Thus, power is dominated by the biological effect size and NH that 
gives the observed number of heterozygotes (or the number of captured minor allele copies) 
in the sample.
Figure 2 shows the biological effect size that can be detected at 80% power for a fixed 
number of observed heterozygotes in the pedigree in Fig. 1. We show the range of 5 to 70 
heterozygotes/MACs. The lower bound of five minor allele copies required before testing is 
based on simulations that show that the resulting test distribution under the null hypothesis 
conforms with expectation (i.e., there is no excess type I error). As the number of captured 
MACs increases, power to detect moderate biological effect sizes improves. As a rough 
reference, a biological effect size of 4.5 SDU approaches nearly monogenic penetrance. 
Figure 2 also shows the effect of augmenting this pedigree with an additional 20,000 
unrelated controls (the total sample size of the WGSPD consortium [8]). For the case of the 
rarest of variants (i.e., private variants), there is a relatively minor improvement in power 
with increased numbers of controls who are highly unlikely to harbor the rare variant. Thus, 
the recruitment of related individuals acts like an ascertainment bias to increase power by 
increasing the probability of capturing additional copies of rare variants that appear in the 
founders of the sampled lineages.
The prior discussion focuses on ascertainment of families simply through lineage size in 
order to maximize the capture of rare variants that originate in pedigree founders. However, 
additional power benefits accrue through additional ascertainment through disease or 
phenotype. For example, the co-segregation of rare variation and disease status in multiplex 
families can amplify association signals [31, 83, 84]. For the study of rare sequence 
variation, an implication of Mendelian transmission is that the required sample sizes can be 
orders of magnitude smaller for families than those required for designs based on unrelated 
subjects [85], particularly if sequence information is combined with linkage methods [28] in 
pedigrees of 20–25 individuals or larger [29], when comparing affected sibling pairs [30] or 
when searching for shared genomic segments [31]. For the rarest variants, large pedigrees 
have better power for detection of linkage/association when compared to equivalent-sized 
samples of smaller families [86] or unrelated subjects [80, 87, 88]. Family-based cohorts 
have substantially greater power than unrelated cases to detect rare genetic effects given an 
equivalent number of sampled individuals [89, 90].
An additional advantage to studying families is that, in contrast to unrelated individuals, the 
analysis of phenotypes among family members is constrained for genetic background (e.g., 
minimizes the impact of population admixture and stratification [91, 92]). Given that 
analytic techniques developed to correct for population stratification in common variant 
studies maybe less effective when the focus is on rare variants [93, 94], observations that 
pedigree-based experiments appear to be robust to population stratification are of particular 
importance [92]. In addition, reduced environmental variation among family members can 
reduce noise, improving statistical power to observe genotype-phenotype associations [95]. 
Shared familial environments also can alter the potential to observe signals resulting from 
gene-environment interactions. Pedigree-based designs allow for the investigation of de novo 
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mutations, parent of-origin effects [96], transmission bias [97], phasing [98, 99], and 
compound heterozygosity [100, 101]. Finally, when pedigrees have multiple affected 
members it is often presumed that the same inherited mutation on a similar genetic 
background causes the illness in each case. This assumption appears to be better supported 
when a kindred includes at least three affected individuals [102, 103]. Although 
unambiguously demonstrating phenocopies is difficult in multifactorial phenotypes [104], it 
is possible that family-based studies provide a method for detecting phenocopies if a rare 
mutation appears to segregate with affection status in the pedigree[102]. To the extent that 
the segregating mutation also influences an illness endophenotype (see below), contrasting 
the endophenotype from the putative phenocopy and family members who carry the variant 
could provide further evidence of the non-genetic origin of the illness in that individual.
Rare variants, pedigrees and psychotic and affective disorders
Recently, Steinberg and colleagues [105] examined a single Icelandic pedigree with ten 
psychotic individuals (six schizophrenia, two schizoaffective disorder and two psychotic 
bipolar disorder) using WGS and long-range phasing. All affected individuals carried a rare 
nonsense mutation in RBM12 (RNA-binding-motif protein 12) resulting in a truncated 
protein lacking a predicted RNA-recognition motif while few unaffected had the mutation (p 
= 2.2 × 10−4). A Finnish family with a second loss of function RBM12 mutation replicated 
the finding (p = 0.020). Although the truncating mutation was not fully penetrant for 
psychosis, non-psychotic carriers were similar to their psychotic relatives in terms of 
neurocognitive endophenotypes, educational attainment and disability benefits received. 
Together, these data strongly associate RBM12 with psychosis risk and demonstrate the 
potential for gene identification using WGS and extended pedigrees.
Homann and colleagues [106] performed WGS on nine families with at least three members 
with schizophrenia. In one of these families, seven siblings with schizophrenia spectrum 
disorders carried a private missense variant within the SHANK2 gene. In a separate family, 
four affected siblings carried a novel private missense variant in the SMARCA1 gene. In a 
conceptually similar study, Timms and colleagues [107] used exome sequencing to examine 
rare nonsynonymous variants in five multiplex schizophrenia families. One pedigree carried 
a missense and frameshift substitution of GRM5, while another family had a missense 
substitution in PPEF2; both are genes that directly interact with the NMDA system [107]. 
Three pedigrees had missense substitutions within LRP1B, which is putatively related to the 
NMDA receptor. While these findings require replication and biological validation, 
nominated genes are reasonable empirical candidates for psychosis risk, warranting further 
research.
As can be seen in Table 1, an increasing number of family-based sequencing studies 
involving affective and psychotic disorders are being published, often with very small 
sample sizes. While findings from most of these studies have yet to be replicated, several of 
the more recent studies, particularly those conducted in population isolates [108] with larger 
sample sizes, provide strong candidate genes for these disorders.
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The foregoing discussion focused on identifying individual rare variants or CNVs strongly 
associated with risk for affective or psychotic disorders. The focus on a single variant or 
CNV is analytically consistent with method developed for monogenic disorders [109]. 
However, there is growing evidence that even in the case of a highly penetrant mutation, an 
individual’s genetic background contributes to illness risk [110]. For example, among 
individuals with a 22q11 deletion, rare CNVs outside of the 22q11 deletion region 
significantly contribute to schizophrenia risk [68]. Similarly, among members of a large 
multiplex pedigree with a balanced chromosomal translocation (1q42–11q14.3) associated 
with affective and psychotic disorders [111], common and rare variation in other areas of the 
genome appear to increase illness risk [112]. These finding are consistent with observations 
that genetic variation outside of the focal “causal” gene are often necessary for disease 
expression in monogenic disorders [103]. Together, these results serve as a reminder of the 
difficulty of making casual inferences in human genetics.
Cost-effectiveness of wgs in families
Family-based designs are cost effective. Given that genetic relationships between family 
members are known, WGS can be imputed [113] for individuals who have sparse genotype 
data, decreasing the effective cost per sample [114, 115]. This pedigree-based imputation or 
“pseudo-sequencing” is particularly effective for rarer, segregating variants [116]. Typically, 
this approach consists of two steps: (1) form optimal sub-pedigrees that maximize phase and 
IBD information and (2) pseudo-sequence each sub-pedigree. The resulting output will 
contain the expected number of copies for the tested allele (dosage), shown to yield the most 
power when used in association testing versus choosing most probable genotypes [90]. 
Livne and colleagues [114] applied similar methods (a combination of pedigree-based and 
LD-based imputation), reporting > 99% accuracy over the full range of allele frequencies. 
With data from the “Genetics of Brain Structure and Function” study, we found that pseudo-
sequenced individuals show 97% accuracy for rare heterozygous variants and 99% for rare 
homozygotes compared to ExomeChip genotypes. Despite the accuracy of these “pseudo-
sequencing” methods, once a rare variant is associated with a specific trait, we advocate 
directly genotyping that variant across the full sample to confirm the imputation.
Pedigree-based sequence data allows a level of quality control not available for population 
studies. Genotyping errors occur when the “true” genotype is not identical to the genotype 
determined after subsequent genotyping. These errors, can occur at every step of the 
genotyping process and cannot be fully eradicated as genotyping methods are not 
completely accurate [117]. Genotyping errors can lead to a number of possible biases, 
including an artificial excess of homozygotes [118], a false departure from Hardy–Weinberg 
equilibrium [119], an overestimation of inbreeding [118] or unreliable inferences about 
population substructures [120]. Incorporating evidence of Mendelian transmission of alleles 
between parents and offspring in pedigree data can dramatically reduce genotyping errors 
[121], even allowing for the detection of de novo mutation and the fact that 25% of typing 
errors may be Mendelian-compatible [122].
Glahn et al. Page 9
Mol Psychiatry. Author manuscript; available in PMC 2020 February 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Using families to model environmental risk factors
Mental illness results from multiple genetic and environmental factors and, likely, from their 
interactions. In contrast to genetic data, the environment is ever changing and its impact can 
vary with developmental stage, making the study of non-genetic influences on mental illness 
risk particularly challenging. Yet, most studies of environmental risk factors for mental 
illness (e.g., [123–125.]) do not explicitly account for genetic background. For example, the 
incidence of schizophrenia is higher among individuals living in urban areas than to those 
living in rural areas [126, 127], which presumably reflects an environmental risk factor for 
psychotic disorders. However, even this classic environmental risk factor has an appreciable 
genetic component, where “urbanicity” is to some extent conditioned upon family history 
for schizophrenia [128] and individuals living in urban areas have higher polygenetic risk for 
the disorder than those living in rural areas [129]. Thus, Epidemiological studies designed to 
identify risk factors for mental illnesses should also include genetic information [124]. 
Pedigree-based designs, in addition to being of value for detecting genetic loci, enhance the 
study of environmental factors influencing mental illness as they provide a relatively 
straightforward method for optimally statistically controlling for genetic influences. 
Recently, we developed a best linear unbiased predictor estimation procedure to obtain 
individual-level estimates of genome-wide genetic effects [130]. This procedure uses all 
phenotypic information available for an individual and his or her relatives to infer the 
underlying genetic component of a phenotype. The estimated genetic value is then 
subtracted from the original phenotypic value to obtain an estimated environmental value 
devoid of the average additive genetic signal. Polygenic effect estimates derived in this way 
can be used to control for genetic influence when investigating non-genetic (environmental) 
contributions to mental illness.
Endophenotypes
An endophenotype is a trait influenced by some or all of the genes predisposing to an illness 
[131, 132]. As endophenotypes are measureable in both affected and unaffected individuals, 
they are theoretically capable of providing greater statistical power to localize and identify 
disease-related genes than affection status alone [26, 133]. Furthermore, as demonstrated by 
Steinberg and colleagues [105], endophenotypes can provide insight into unaffected carriers 
of putatively causal illness variants. Despite the consistent use of endophenotypes in other 
areas of human disease genetics (sometimes referred to as allied phenotypes or simply risk 
factors), their application in larger scale psychiatric genetics studies designed to identify 
novel risk loci has been limited [132]. However, methods for empirically selecting 
endophenotypes for specific illnesses based upon shared genetic covariance using related 
subjects [134, 135] or based upon common variants [46] have been developed and 
overlapping genetic influences for cognitive, electrophysiological, neuroimaging and 
transcriptional measures and various psychiatric disorders have been discovered [132]. 
Regardless of the genetic design employed, we strongly advocate deep phenotyping, 
including quantitative diagnostic/symptom measures and cognitive, imaging and molecular 
endophenotypes. While myriad of potential endophenotypes for psychotic and affective 
disorders exist, selecting those that are heritable, genetically correlated with illness risk and 
amenable to large scale data collection is critical [132]. Tools for such deep phenotyping are 
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now available in the public domain (e.g., PhenX Early Psychosis Translational Research 
Collection https://www.phenxtoolkit.org/index.php?pageLink=browse.nimh.eptr).
Effects of ascertainment
How families are selected for study may influence both the phenotypic spectrum of the 
sample and the underlying genetic contributors. Probands recruited as part of families may 
differ from those recruited as singleton cases, presumably as an effect of selecting 
individuals with intact family relationships. For example, the Consortium on the Genetics of 
Schizophrenia (COGS) examined neurocognitive measures and other endophenotypes in 
families selected through a proband (COGS-1) and in a case-control (COGS-2) study [136]. 
Patients ascertained through the family-based design, compared to case-control, were 
younger, had higher educational attainment, better educated parents and superior 
performance on some neurocognitive tests. Thus, studies that use case-control ascertainment 
may tap into populations with more severe forms of illness that are exposed to less favorable 
factors compared to those ascertained through designs that require family participation. 
However, designs that require multiple affected individuals in a family may result in a more 
severe phenotypic profile and a different underlying genetic architecture as compared to 
simplex families. For example, a comparison of multiplex and simplex ASD families found 
an enrichment of CNVs in ASD risk loci in both but a lower rate of de novo CNVs in the 
multiplex families [137]. Family selection also impacts the distribution of phenotypes 
among unaffected family members, with members of multiplex families generally having 
greater endophenotype impairment than simplex family members [138–140]. In addition to 
enriching for inherited, as opposed to de novo, risk alleles selection on multiplex families 
may enrich for loci of larger effect which are presumably rarer [102, 107, 141].
Pedigree-based whole genome sequencing of affective and psychotic 
disorders consortium
To capitalize on the benefits of family-based designs for variant localization and gene 
identification, we formed an eight-site international consortium to use whole genome 
sequence data and novel analytic methods to identify rare variants that increase risk for 
affective and/or psychotic illness. Initially, participating studies included: individuals from 
large families of Amish and Mennonite descent ascertained for bipolar disorder and living in 
Pennsylvania, Ohio, and Indiana [142, 143]; individuals from 88 multiplex families living in 
Western Australia [144]; persons from extended families living in Costa Rica’s central 
valley who were identified via a sibling pair concordant for either schizophrenia or bipolar 
disorder [145]; large multiplex multigenerational families from Pennsylvania selected for 
schizophrenia [146]; individuals with from Scottish families multiply affected with bipolar 
disorder or schizophrenia [147, 148]; and large extended Mexican–American pedigrees 
living in Texas and selected without regard to phenotype [77]. Our cost-effective approach 
leverages existing DNA, phenotypic data and some existing sequence data from extended 
pedigrees with at least three affected family members. Together, we have marshaled over 
4000 individuals in approximately 269 families (see Table 2). Other research groups who 
have generated WGS in additional well-characterized families are encouraged to join us.
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Conclusion
It is clear that common and rare variants, as well as environmental factors, play a role in risk 
for mental illness. Large meta analytic GWAS have likely localized most or all of the 
common variants with moderate to large effect sizes for the major psychiatric disorders [10]. 
Following this logic, Boyle, Li and Pritchard [10] recently suggested that after the biggest 
hits from GWAS have been identified, “the next most promising step is to hunt for lower-
frequency variants of larger effects” (page 1184). Given the recent progress with common 
variation, it would seem that the field of psychiatric genetics should now capitalize on those 
successes by identifying and characterizing analogous rare variation and confirming those 
previously identified [149]. Extended pedigrees represent an implicit enrichment strategy for 
identifying rare variants since Mendelian transmission maximizes the chance that multiple 
copies will exist in the family. Given this enrichment, the associated improvement in 
statistical power, plus the economic advantages of pseudo-sequencing through genotype 
imputation, we formed the “Pedigree-Based Whole Genome Sequencing of Affective and 
Psychotic Disorders” consortium, a group of international scientists dedicated to using 
family-based designs to identify rare variants that increase risk of psychiatric disorders. 
WGS in multiplex pedigrees provides an important complementary experimental approach 
for identifying genes that confer risk for mental illness.
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Fig. 1. 
Demonstration of rare variant inheritance in a large extended pedigree. One hundred and 
forty-eight individuals from a single large pedigree sampled in our ongoing “Genetics of 
Brain Structure and Function” study are represented. Based on the principals of Mendelian 
inheritance, the pedigree could maximally provide 105 copies of a rare or even private 
mutation originating in a single founder (filled). The figure was created with CraneFoot 
[150]
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Fig. 2. 
Biological effect size for rare variants as a function of minor allele copies (MAC). The blue 
dashed line shows the biological effect size that can be detected at 80% power for a fixed 
number of observed heterozygotes in the pedigree in Fig. 1. As the number of captured 
MACs increases, power to detect moderate biological effect sizes improves. The effect of 
augmenting this pedigree with an additional 20,000 unrelated controls is presented in the 
orange line. For the case of the rarest of variants, there is a relatively minor improvement in 
power with increased numbers of controls who are highly unlikely to harbor the rare variant
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